The agreement with Chr. Hansen, a leading manufacturer of food ingredients, demonstrates commercial viability of Jurag Separations unique separation system and confirms the technology’s attractiveness for scalable and productive solutions in industrial settings.

With the joint venture Chr. Hansen gets access to Jurag Separations patented REED filtration technology, which offers advanced electro-membrane solutions for separation of ionic species directly from fermentation broth as well as from a variety of other complex process streams.

Zymenex has initiated the Phase II part of the clinical trial in seriously ill children with MLD.

Zymenex has initiated the Phase II part of the clinical trial in seriously ill children with MLD.

The trial will hopefully show the way to a cure for the rare and until now incurable disease, Metachromatic Leukodystrophy (MLD), which is diagnosed in children between the ages of 2-5 years and paralyses the nervous system in such a way that the children die.

Santaris Pharma presents positive clinical data on SPC2996 in Chronic Lymphocytic Leukaemia.

Santaris Pharma, the Danish biopharmaceutical company, announced today that SPC2996, the Company’s new RNA Antagonist of Bcl-2, has shown early evidence of efficacy in an initial Phase I/II clinical study in Chronic Lymphocytic Leukaemia (CLL). The results of the study were reported this week at the 2007 Annual Meeting of the American Society of Clinical Oncology, held in Chicago, Illinois.

Santaris Pharma har udviklet den første nye lægemiddelkandidat i verden, som er rettet mod MicroRNA. Lægemiddelkandidaten skal nu videreudvikles af et MicroRNA Forskningskonsortium, som bliver støttet af Højteknologifonden med 10 mio. kr.

Det samlede budget for udviklingspro-jektet er 20 mio kr. MicroRNA Forskningskonsortiet består foruden Santaris Pharma af Center for Biologisk Sekvensanalyse (CBS), DTU samt Institut for Cellulær og Molekylær Medicin på Københavns Universitet MicroRNA, der forekommer naturligt i alle celler, er en nyopdaget klasse af små RNA molekyler, som regulerer aktiviteten af andre gener i cellen.

Ace Biosciences

Ace Biosciences in-licences phase I enterotoxigenic E Coli (ETEC) vaccine from Cambridge Biostability Ltd- Deal involves initial payment, milestone and royalties.

ACE BioSciences A/S, the infectious diseases company and Cambridge BioStability Ltd (CBL), the British biotechnology company have entered a strategic deal whereby ACE BioSciences in-licenses CBL’s ‘HolaVax’, (to be called ACE537) an oral Phase I Enterotoxigenic E Coli (ETEC) vaccine which has the potential to be the first to market in the US and EU and which combats the single biggest cause of travelers diarrhoea.